pexidartinib (China, EU)

Plexxikon MOA pexidartinib China and UK

Targeted Indication Status Sites link to clinicaltrials.gov

KIT-mutant
melanoma

Phase 2

Peking, China
Seoul, Korea
Manchester, UK
London, UK

NCT02975700
NCT02071940

These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation. Image above depicts proposed targeted pathway of the investigational agent(s) in the targeted indication.

Bastian BC, Esteve-Puig R. Journal of Clinical Oncology. 2013; 31(26); 3288-90.